Searchlight Pharma has acquired the Canadian marketing rights for Divigel® from Vertical Pharmaceuticals.
Divigel® is a prescription transdermal estrogen product approved for the treatment of menopause-related symptoms.
Go deeper with GlobalData
Vertical Pharmaceuticals holds the marketing rights to the product in the US and has agreed to help Searchlight in launching the product in Canada.
The transaction is effective from December when Searchlight will commence distribution marketing activities for Divigel® in Canada.
The deal will enable Searchlight to provide a wide range of solutions in the women’s healthcare sector.
Based in Canada, Searchlight Pharma is a speciality healthcare company, while Vertical Pharmaceutical is a US-based pharmaceutical company with a portfolio of women’s healthcare products.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataQ BioMed has entered an agreement with GE Healthcare to acquire cancer palliation therapy Metastron™ for an undisclosed amount.
Q BioMed will own the brand, trademarks, and market authorisations of the drug in 22 countries, as well as all the related intellectual property. It will also receive all the market sales and distribution data from GE.
GE Healthcare will receive the transaction amount as an upfront payment. It is also entitled to receive one sales-based milestone payment and a single digit royalty payment for 15 years.
Q BioMed is a biomedical acceleration and development company, while GE Healthcare is a biotechnology company.
Both companies involved in the transaction are based in the US.
Quest PharmaTech has entered an agreement with OncoCare Therapeutics for the development and commercialisation of its cancer therapy technology in the US.
Quest will receive 45% interest in OncoCare Therapeutics as part of the agreement.
The Quest development pipeline includes two treatments, namely AR 9.6 and ACP-2127. OncoCare will collaborate with Quest on the research and development of the drug.
Canada-based Quest PharmaTech is a pharmaceutical company, while OncoCare Therapeutics is a biopharmaceutical company based in the US.
